Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2868 + anlotinib + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen consists of four agents: - **TQB2868**, a fusion protein that targets PD-1 and TGF-β, acting as an immune checkpoint inhibitor and TGF-β pathway modulator to combat tumor immunosuppression and desmoplastic stroma in pancreatic cancer[1][3]. - **Anlotinib**, a small molecule multikinase inhibitor, primarily targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGGR), and c-Kit, with antiangiogenic and antitumor effects. - **Gemcitabine**, a nucleoside analog chemotherapeutic agent, inhibits DNA synthesis by incorporation into DNA, leading to chain termination and apoptosis[2][6]. - **Nab-paclitaxel**, an albumin-bound nanoparticle formulation of paclitaxel, enhances chemotherapy delivery to tumor cells and stabilizes microtubules, inhibiting cell division and promoting apoptosis[2][4][6]. This four-drug combination is being evaluated as first-line treatment for metastatic or locally advanced pancreatic cancer. Early-phase and pivotal trials showed tolerability and promising antitumor activity with this regimen in pancreatic adenocarcinoma patients[1][3][7].
- Other names
- TQB2868 + anlotinib + gemcitabine + nab-paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))PDGFRA (Platelet-derived growth factor receptor alpha)TGFB (GARP–latent transforming growth factor beta 1 complex)VEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR (FGFR family)
Beyond the preview
Go deeper on TQB2868 + anlotinib + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2868 + anlotinib + gemcitabine + nab-paclitaxel.